1 New Drug Development ........................................... 1
1.1 Introduction ......................................................... 1
1.2 Origin and Goals of the Book ................................. 2
1.3 The Discipline of Statistics ................................. 2
1.4 A Lifecycle Perspective on Drug Development ........... 3
1.5 Design, Conduct, and Analysis ............................ 4
1.5.1 Compelling Evidence ........................................ 4
1.6 Drug Discovery .................................................. 4
1.7 Nonclinical Development Programs ...................... 5
1.8 Clinical Development Programs ........................... 5
1.8.1 Ethical Conduct .............................................. 6
1.8.2 Different Studies in a Clinical Development Program .... 7
1.9 Manufacturing .................................................. 8
1.10 Definitions of Clinical Research and Clinical Trials ..... 9
1.10.1 Clinical Research .......................................... 9
1.10.2 Clinical Trials ............................................ 10
1.11 Operational Execution ......................................... 10
1.12 The Central Importance of Biological Considerations ... 10

2 The Regulatory Environment ..................................... 11
2.1 Introduction ......................................................... 11
2.1.1 Goals of the ICH ............................................. 12
2.2 The Food and Drug Administration ....................... 12
2.2.1 The Code of Federal Regulations ........................ 13
2.3 cGMP, cGLP, and cGCP ........................................ 14
2.4 Regulatory Aspects of New Drug Development .......... 14
2.5 Sponsor and Regulatory Agency Responsibilities .......... 15
2.6 The Investigational New Drug Application ................ 15
2.6.1 Review of the Investigational New Drug Application .... 17
## 3 Drug Discovery

### 3.1 Introduction

- **3.1.1 Small Molecule Drug Candidates**
- **3.1.2 Biopharmaceutical Drug Candidates**

### 3.2 Overview of Pharmaceutics, Pharmacokinetics, and Pharmacodynamics

- **3.2.1 Drug Receptors**
- **3.2.2 The Pharmacodynamic Phase**
- **3.2.3 The Pharmacokinetic Phase**
- **3.2.4 The Pharmaceutical Phase**

### 3.3 Medicinal Chemistry

- **3.3.1 Drug Molecules**
- **3.3.2 Macromolecules, Receptors, and Drug Targets**

### 3.4 Cheminformatics, Bioinformatics, and Computer-Aided Molecular Design

- **3.4.1 Bioinformatics**

### 3.5 Biologicals

- **3.5.1 Molecular Genetics and Proteins**
- **3.5.2 Protein Structures**
- **3.5.3 Recombinant DNA Technology**
- **3.5.4 Recombinant Proteins As Drugs**
- **3.5.5 Discovery and Development of Biopharmaceuticals**

### 3.6 Moving to Nonclinical Research

Further Readings
4.4.2 Exploratory Toxicology Studies .................. 40
4.4.3 Pre-FIH Regulatory Toxicology Studies .......... 41
4.4.4 Post-FIH Regulatory Toxicology Studies .......... 41
4.4.5 Dose Range-Finding Toxicology .................. 41
4.4.6 Genotoxicity .................................. 42
4.5 Assessment of QT Interval Prolongation .......... 42
  4.5.1 Long QT Syndrome: Underlying Molecular
      Biology ........................................ 43
  4.5.2 Drug-Induced QT Interval Prolongation ......... 44
  4.5.3 Associated Nonclinical Testing ................. 45
  4.5.4 Short QT Syndrome .......................... 45
Further Readings .................................... 46

5 Designing Clinical Trials ........................ 47
  5.1 Introduction .................................. 47
  5.2 Classification of Clinical Trials ................ 47
  5.3 Human Pharmacology Trials ..................... 49
  5.4 Clinical Pharmacokinetics and Pharmacodynamics .. 51
      5.4.1 Pharmacokinetic Parameters .................. 52
      5.4.2 Fasting and Fed Pharmacokinetics .......... 52
      5.4.3 Absorption and Bioavailability ............ 53
      5.4.4 Distribution ............................... 54
      5.4.5 Metabolism ................................ 54
      5.4.6 Elimination/Clearance ..................... 55
  5.5 Therapeutic Exploratory Trials .................. 55
  5.6 Therapeutic Confirmatory Trials ................ 56
  5.7 Therapeutic-Use Trials ......................... 56
  5.8 Study Design .................................. 56
  5.9 Ethical Aspects of Design ....................... 57
  5.10 Study Design in Drug Clinical Trials .......... 57
      5.10.1 The Parallel Group Design ................ 58
      5.10.2 The Cross-over Design ................... 59
      5.10.3 Respective Advantages of the Parallel Group
            and Cross-over Designs .................... 59
      5.10.4 Focus on the Parallel Group Design in This
            Book ........................................ 60
  5.11 Central Principles of Experimental Design
      in Clinical Trials ............................. 60
      5.11.1 Replication .............................. 61
      5.11.2 Randomization ............................ 61
      5.11.3 Local Control ............................ 64
      5.11.4 Good Design Simplifies and Validates the
            Accompanying Analyses ..................... 64
      5.11.5 Sample Size Estimation ................... 65
5.12 The Clinical Study Protocol ........................................ 65
5.12.1 Inclusion and Exclusion Criteria .......................... 66
5.12.2 The Primary Objective ....................................... 66
Further Readings .......................................................... 67

6 Conducting Clinical Trials I: Experimental Methodology ...... 69
6.1 Introduction ......................................................... 69
6.2 Blood Pressure Measurement in Clinical Trials ............... 70
6.2.1 Hypertension .................................................. 70
6.2.2 Surrogate Endpoints in Clinical Trials .................... 71
6.2.3 Arterial Blood Pressure ...................................... 72
6.2.4 Assessing Blood Pressure Change over Time ............ 73
6.2.5 A Cautionary Tale: Blood Pressure Measurement at Your Doctor’s Office ........................................ 74
6.2.6 A Cautionary Tale for Clinical Trial Blood Pressure Measurements .............................................. 75
6.3 Central Labs ......................................................... 75
6.3.1 Operational Considerations ................................ 76
6.4 Core ECG Labs ..................................................... 77
6.5 The Case Report Form ............................................. 77
Further Readings .......................................................... 78

7 Conducting Clinical Trials II: Operational Execution ......... 79
7.1 Introduction ......................................................... 79
7.2 The Outsourcing Process ........................................ 80
7.3 Feasibility Evaluations ........................................... 80
7.3.1 More Extensive Feasibility Evaluations .................. 81
7.3.2 Feasibility Reporting ......................................... 82
7.4 Standard Operating Procedures ................................. 82
7.4.1 Balancing the Degree of Flexibility Within an SOP .......... 83
7.4.2 The Necessity of Implementing and Maintaining SOPs .......... 83
7.5 Project Management ............................................... 84
7.6 Site and Investigator Recruitment ............................... 85
7.6.1 Principal Investigators ...................................... 85
7.6.2 Responsibilities of Principal Investigators ................ 86
7.6.3 Potential Principal Investigators in Private Practice Settings ............................................. 86
7.6.4 Potential Principal Investigators at Larger Medical Institutions ........................................... 86
7.6.5 Principal Investigator Training ............................. 87
7.7 Subject Recruitment and Retention ............................. 88
7.7.1 Subject Recruitment ........................................ 88
7.7.2 Subject Retention ............................................ 89
9 Statistical Significance .................................................. 115
  9.1 Introduction ....................................................... 115
  9.2 Creating a Research Question and Associated Hypotheses ...... 115
    9.2.1 The Research Hypothesis ................................... 115
    9.2.2 The Null Hypothesis ........................................ 116
  9.3 Precise Expression of the Research Hypothesis and the Null Hypothesis: The Concept of Statistical Significance ... 116
  9.4 Hypothesis Testing ................................................ 117
  9.5 Conducting a Statistical Test and Obtaining a Test Statistic .................................................. 118
  9.6 The Independent Groups t-Test .................................. 118
    9.6.1 Degrees of Freedom ......................................... 119
    9.6.2 Format of Results from an Independent Groups t-Test .... 120
    9.6.3 The p-Value: Its Definition and Meaning ................... 121
    9.6.4 The p-Value and Hypothesis Testing ....................... 122
    9.6.5 Two More Examples of Results from an Independent Groups t-Test .................................................. 122
  9.7 The Dependent Measures t-Test .................................. 123
  9.8 Analysis of Variance .............................................. 125
  9.9 One-Factor Independent Groups ANOVA ......................... 125
    9.9.1 The Test Statistic in ANOVA ................................ 126
    9.9.2 Calculation of the F-Test ................................... 126
    9.9.3 A Further Analytical Step: Multiple Comparisons .......... 128
  9.10 General Comments on Multiple-Comparison Testing .......... 130
    9.10.1 Type I Errors and Type II Errors ......................... 130
  9.11 Possible Clinical Interpretations of Statistical Results .... 132
10 Clinical Significance .................................................. 135
  10.1 Introduction ...................................................... 135
  10.2 The Logic of Confidence Intervals ................................ 135
  10.3 Confidence Intervals for a Sample Mean ................. 136
    10.3.1 A More Precise Definition of a Confidence Interval .......... 137
  10.4 Confidence Intervals for the Difference Between Treatment Group Means .................................................. 137
  10.5 Relationship of the 95% CI and 99% CI to the 0.05 and 0.01 p-Values .................................................. 138
  10.6 The Additional Benefit of Using Confidence Intervals .... 139
    10.6.1 Clinical Relevance and Clinically Relevant Differences .......... 139
11 Sample Size Estimation .......................................................... 143
  11.1 Introduction ................................................................. 143
  11.2 Ethical Issues in Sample Size Estimation ......................... 144
  11.3 Variables Involved in Sample Size Estimation ................... 145
  11.4 Type I and Type II Errors ............................................. 146
    11.4.1 The Implications of Type I and Type II Errors ............ 146
  11.5 Choosing the Variables Needed for Sample Size Estimation .... 147
    11.5.1 Alpha and Beta ................................................... 147
    11.5.2 The Treatment Effect, Its Variance, and the Standardized Treatment Effect .......................... 148
  11.6 Using the Appropriate Formula to Yield the Sample Size ...... 148
  11.7 Influences on the Sponsor’s Choice of These Values ........... 149
  11.8 Choosing the Objective(s) on Which to Base the Sample Size Estimation ........................................ 150
  11.9 Other Issues to Keep in Mind ........................................ 150

12 General Safety Assessments .................................................. 153
  12.1 Introduction ................................................................. 153
  12.2 Operationalizing the Term Drug Safety ................................ 153
    12.2.1 Perspectives of Regulators and Prescribing Physicians on Safety Data .................................. 154
  12.3 General Safety Assessments ............................................ 155
    12.3.1 Extent of Exposure ................................................ 156
    12.3.2 Adverse Events ................................................... 156
    12.3.3 Common Laboratory Tests ....................................... 157
    12.3.4 Vital Signs ........................................................ 159
  12.4 Acquisition and Management of Safety Data ....................... 159
    12.4.1 Adverse Events ................................................... 159
    12.4.2 Serious Adverse Event Data .................................... 160
  12.5 Analysis Populations .................................................... 161
  12.6 Presentation of Safety Data ........................................... 161
    12.6.1 Descriptive Approaches to Safety Data ...................... 162
    12.6.2 Time-to-Event Analysis ......................................... 163
    12.6.3 Differences Between Approaches to Safety and Efficacy Data .............................................. 164

Further Readings ................................................................. 164

13 Efficacy Assessment ............................................................ 165
  13.1 Introduction ................................................................. 165
    13.1.1 Superiority, Equivalence, and Noninferiority Trials ........ 165
    13.1.2 Group Sequential and Adaptive Study Designs ............ 166
  13.2 Analysis Populations .................................................... 166
    13.2.1 The Intent-to-Treat Population ............................... 167
    13.2.2 The Per-protocol Population ................................. 167
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.2.3</td>
<td>Using Both Analysis Populations</td>
<td>167</td>
</tr>
<tr>
<td>13.2.4</td>
<td>Missing Data</td>
<td>168</td>
</tr>
<tr>
<td>13.3</td>
<td>Hypothesis Testing Is Integral to All of the Designs Discussed</td>
<td>168</td>
</tr>
<tr>
<td>13.4</td>
<td>Superiority Trials</td>
<td>169</td>
</tr>
<tr>
<td>13.4.1</td>
<td>Well-Defined Study Objectives and Endpoints</td>
<td>169</td>
</tr>
<tr>
<td>13.4.2</td>
<td>Analysis of Covariance</td>
<td>170</td>
</tr>
<tr>
<td>13.4.3</td>
<td>Subgroup Analysis</td>
<td>171</td>
</tr>
<tr>
<td>13.5</td>
<td>Equivalence Trials</td>
<td>172</td>
</tr>
<tr>
<td>13.5.1</td>
<td>Why the Hypothesis Testing Strategy Is Different Here</td>
<td>173</td>
</tr>
<tr>
<td>13.5.2</td>
<td>Establishing the Equivalence Margin</td>
<td>174</td>
</tr>
<tr>
<td>13.5.3</td>
<td>Hypothesis Construction and Testing</td>
<td>175</td>
</tr>
<tr>
<td>13.5.4</td>
<td>Statistical Analysis and Clinical Judgment Working Together</td>
<td>176</td>
</tr>
<tr>
<td>13.6</td>
<td>Noninferiority Trials</td>
<td>176</td>
</tr>
<tr>
<td>13.6.1</td>
<td>Establishing the Noninferiority Margin</td>
<td>176</td>
</tr>
<tr>
<td>13.6.2</td>
<td>Hypothesis Construction and Testing</td>
<td>176</td>
</tr>
<tr>
<td>13.6.3</td>
<td>Statistical Analysis and Clinical Judgment Working Together</td>
<td>177</td>
</tr>
<tr>
<td>13.7</td>
<td>Group Sequential Designs</td>
<td>177</td>
</tr>
<tr>
<td>13.7.1</td>
<td>Interim Analyses in Group Sequential Trials</td>
<td>178</td>
</tr>
<tr>
<td>13.7.2</td>
<td>Data Monitoring Committees</td>
<td>178</td>
</tr>
<tr>
<td>13.7.3</td>
<td>Statistical Methodology for Interim Analysis</td>
<td>179</td>
</tr>
<tr>
<td>13.7.4</td>
<td>Ethical Considerations in Early Termination</td>
<td>182</td>
</tr>
<tr>
<td>13.8</td>
<td>Adaptive Designs</td>
<td>183</td>
</tr>
<tr>
<td>13.8.1</td>
<td>Protocol Amendments</td>
<td>183</td>
</tr>
<tr>
<td>13.8.2</td>
<td>Increasing Awareness of Adaptive Designs</td>
<td>184</td>
</tr>
<tr>
<td>13.8.3</td>
<td>Regulatory Guidance for Adaptive Designs</td>
<td>185</td>
</tr>
<tr>
<td>13.9</td>
<td>Bayesian Approaches to Analyzing Clinical Trials</td>
<td>186</td>
</tr>
<tr>
<td>13.10</td>
<td>Meta-analysis</td>
<td>186</td>
</tr>
<tr>
<td>13.10.1</td>
<td>Introduction to Meta-analysis</td>
<td>187</td>
</tr>
<tr>
<td>13.10.2</td>
<td>The Basic Steps</td>
<td>188</td>
</tr>
<tr>
<td>13.10.3</td>
<td>Choice of the Summary Statistic Representing the Treatment Effect of Interest</td>
<td>189</td>
</tr>
<tr>
<td>13.10.4</td>
<td>Data Analysis</td>
<td>189</td>
</tr>
<tr>
<td>13.10.5</td>
<td>Evaluating Robustness</td>
<td>191</td>
</tr>
<tr>
<td>13.10.6</td>
<td>Dissemination of Results and Conclusions of a Meta-analysis</td>
<td>191</td>
</tr>
<tr>
<td>13.11</td>
<td>Therapeutic Use Trials</td>
<td>192</td>
</tr>
<tr>
<td>13.11.1</td>
<td>Large Simple Therapeutic Trials</td>
<td>192</td>
</tr>
<tr>
<td>Further Readings</td>
<td></td>
<td>193</td>
</tr>
</tbody>
</table>

14 Cardiac and Cardiovascular Safety Assessments | 195 |
| 14.1 | Introduction | 195 |
| 14.2 | A Three-Component Risk Exclusion Model | 196 |
14.2.1 Confidence Intervals Facilitate the Determination of Thresholds of Regulatory Concern

14.3 Cardiac Safety Assessment: A Brief History

14.4 Obtaining QTc Data from QT Measurements

14.5 The Thorough QT/QTc Study
   14.5.1 Design of the TQT Study
   14.5.2 TQT Study Conduct
   14.5.3 Statistical Analysis
   14.5.4 Ramifications of Interpretations by Sponsors and Regulatory Agencies

14.6 FDA Guidance on Excluding Unacceptable Cardiovascular Risk in the Development of Antidiabetic Drugs for Type 2 Diabetes Mellitus
   14.6.1 Clinical Trials to Be Conducted
   14.6.2 Choice of Subject Populations
   14.6.3 Choice of Cardiovascular Endpoints
   14.6.4 Endpoint Adjudication
   14.6.5 The Required Meta-analysis
   14.6.6 A Dedicated Large (Simple) Cardiovascular Trial
   14.6.7 An Additional Consideration for Safety Meta-analyses

14.7 An Example of a Real Safety Meta-analysis

14.8 Potential Regulatory Thresholds of Interest for Other Cardiovascular Parameters

Further Readings

15 Manufacturing Small Molecule Drugs and Biologicals

15.1 Introduction

15.2 Nonclinical Development

15.3 Drug Products for Clinical Trials
   15.3.1 Need for the Investigative Drug and the Control Drug
   15.3.2 Blinding of Drug Products for Clinical Trials
   15.3.3 Packaging and Distributing Clinical Drug Products

15.4 Commercial Manufacturing

15.5 Quality Control: Building Quality into the Process

15.6 Stability Studies

15.7 Immediate Release and Modified Release Tablets and Capsules

15.8 Recombinant Protein Biologicals
   15.8.1 Commercial-Scale Manufacturing

Further Readings
## 16 Postmarketing Surveillance

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.1 Introduction</td>
<td>221</td>
</tr>
<tr>
<td>16.2 Limitations of Preapproval Clinical Trials</td>
<td>222</td>
</tr>
<tr>
<td>16.3 Individual Differences in Drug Response</td>
<td>223</td>
</tr>
<tr>
<td>16.3.1 Hepatic Impairment</td>
<td>223</td>
</tr>
<tr>
<td>16.3.2 Renal Insufficiency</td>
<td>224</td>
</tr>
<tr>
<td>16.3.3 The Elderly</td>
<td>224</td>
</tr>
<tr>
<td>16.3.4 Pediatric Populations</td>
<td>225</td>
</tr>
<tr>
<td>16.4 Postmarketing Surveillance</td>
<td>226</td>
</tr>
<tr>
<td>16.5 The 2005 CDER Report to the Nation</td>
<td>227</td>
</tr>
<tr>
<td>16.6 The Institute of Medicine’s 2006 Report on Drug Safety</td>
<td>228</td>
</tr>
<tr>
<td>16.7 The Food and Drug Administration Amendments Act of 2007</td>
<td>229</td>
</tr>
<tr>
<td>16.8 The FDA’s 2008 Sentinel Initiative</td>
<td>230</td>
</tr>
<tr>
<td>16.8.1 The Science of Safety</td>
<td>230</td>
</tr>
<tr>
<td>16.8.2 Active Surveillance</td>
<td>231</td>
</tr>
</tbody>
</table>

Further Readings: 231

## 17 Main Themes and Concluding Comments

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.1 Introduction</td>
<td>233</td>
</tr>
<tr>
<td>17.2 Ethical Considerations</td>
<td>234</td>
</tr>
<tr>
<td>17.3 Design, Methodology, Operations, and Analysis</td>
<td>235</td>
</tr>
<tr>
<td>17.3.1 Reducing Bias and Improving Precision</td>
<td>235</td>
</tr>
<tr>
<td>17.3.2 Our Definition of Statistics Revisited</td>
<td>236</td>
</tr>
<tr>
<td>17.3.3 Numerical Representations of Biological Information</td>
<td>236</td>
</tr>
<tr>
<td>17.3.4 Some Thoughts on the $p$-Value</td>
<td>237</td>
</tr>
<tr>
<td>17.4 Confidence Intervals and Clinical Significance</td>
<td>238</td>
</tr>
<tr>
<td>17.5 Pharmacokinetics and Pharmacodynamics</td>
<td>238</td>
</tr>
<tr>
<td>17.6 Decision-Making</td>
<td>239</td>
</tr>
<tr>
<td>17.6.1 The Subjective Nature of Many Decisions</td>
<td>239</td>
</tr>
<tr>
<td>17.6.2 Determining Thresholds of Regulatory Concern</td>
<td>241</td>
</tr>
<tr>
<td>17.7 Benefit–Risk Considerations</td>
<td>241</td>
</tr>
<tr>
<td>17.8 Biological Considerations Pervade Our Discussions</td>
<td>241</td>
</tr>
<tr>
<td>17.8.1 Biological Underpinnings of Precision Medicine</td>
<td>242</td>
</tr>
<tr>
<td>17.8.2 Pharmacogenetics</td>
<td>242</td>
</tr>
<tr>
<td>17.8.3 Pharmacogenomics</td>
<td>243</td>
</tr>
<tr>
<td>17.8.4 Pharmacoproteomics</td>
<td>243</td>
</tr>
<tr>
<td>17.9 Integrated Pharmaceutical Medicine</td>
<td>244</td>
</tr>
<tr>
<td>17.10 Concluding Comments</td>
<td>245</td>
</tr>
</tbody>
</table>

References: 247

Index: 251
New Drug Development
An Introduction to Clinical Trials: Second Edition
Turner, J.R.
2010, XXV, 256 p., Hardcover